IMPEL PHARMACEUTICALS INC (IMPL) Stock Price & Overview
NASDAQ:IMPL • US45258K1097
Current stock price
The current stock price of IMPL is 0.2411 USD. Today IMPL is down by -41.79%. In the past month the price decreased by -32.08%. In the past year, price decreased by -93.3%.
IMPL Key Statistics
- Market Cap
- 5.762M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.41
- Dividend Yield
- N/A
IMPL Stock Performance
IMPL Stock Chart
IMPL Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to IMPL. When comparing the yearly performance of all stocks, IMPL is a bad performer in the overall market: 98.54% of all stocks are doing better.
IMPL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IMPL. Both the profitability and financial health of IMPL have multiple concerns.
IMPL Earnings
IMPL Forecast & Estimates
8 analysts have analysed IMPL and the average price target is 40.8 USD. This implies a price increase of 16822.44% is expected in the next year compared to the current price of 0.2411.
For the next year, analysts expect an EPS growth of 64.5% and a revenue growth 128.2% for IMPL
IMPL Groups
Sector & Classification
IMPL Financial Highlights
Over the last trailing twelve months IMPL reported a non-GAAP Earnings per Share(EPS) of -4.41. The EPS increased by 3.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -204.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMPL Ownership
IMPL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.96 | 362.828B | ||
| AMGN | AMGEN INC | 15.51 | 187.828B | ||
| GILD | GILEAD SCIENCES INC | 15.64 | 171.453B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.47 | 113.963B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 78.412B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.05 | 40.854B | ||
| INSM | INSMED INC | N/A | 29.992B | ||
| NTRA | NATERA INC | N/A | 27.569B | ||
| BIIB | BIOGEN INC | 11.77 | 26.995B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.13 | 23.31B | ||
| MRNA | MODERNA INC | N/A | 20.276B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 18.929B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMPL
Company Profile
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 160 full-time employees. The company went IPO on 2021-04-23. The firm has designed its Precision Olfactory Delivery (POD) technology to target the vascular-rich upper nasal space, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, provider, or caregiver. The Company’s product, Trudhesa, is a liquid formulation of dihydroergotamine (DHE), administered to the upper nasal space using its proprietary POD technology for the acute treatment of migraine headaches with or without aura in adults. The firm is developing its product candidate, INP105, as an upper nasal formulation of olanzapine administered using its POD technology for the treatment of agitation and aggression associated with autism spectrum disorder (ASD).
Company Info
IPO: 2021-04-23
IMPEL PHARMACEUTICALS INC
201 Elliott Ave. W, Suite 260
Seattle WASHINGTON US
CEO: Adrian Adams
Employees: 160
Phone: 12065681466
IMPEL PHARMACEUTICALS INC / IMPL FAQ
What does IMPL do?
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 160 full-time employees. The company went IPO on 2021-04-23. The firm has designed its Precision Olfactory Delivery (POD) technology to target the vascular-rich upper nasal space, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, provider, or caregiver. The Company’s product, Trudhesa, is a liquid formulation of dihydroergotamine (DHE), administered to the upper nasal space using its proprietary POD technology for the acute treatment of migraine headaches with or without aura in adults. The firm is developing its product candidate, INP105, as an upper nasal formulation of olanzapine administered using its POD technology for the treatment of agitation and aggression associated with autism spectrum disorder (ASD).
What is the current price of IMPL stock?
The current stock price of IMPL is 0.2411 USD. The price decreased by -41.79% in the last trading session.
Does IMPEL PHARMACEUTICALS INC pay dividends?
IMPL does not pay a dividend.
How is the ChartMill rating for IMPEL PHARMACEUTICALS INC?
IMPL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.